Anthrax vaccination strategies

Molecular Aspects of Medicine

Volumn 30, Issue 6, 2009, Pages 490-502

  Cybulski Jr , Robert J ^a   Sanz, Patrick ^a   O'Brien, Alison D ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Anthrax; Bacillus anthracis; Vaccine

Indexed keywords

ADJUVANT; ALUMINUM POTASSIUM SULFATE; ANTHRAX VACCINE; ANTIBIOTIC AGENT; CPG OLIGODEOXYNUCLEOTIDE; MONOCLONAL ANTIBODY; RECOMBINANT ANTIGEN; VIRULENCE FACTOR;

ANTHRAX; BACILLUS ANTHRACIS; CHEMOPROPHYLAXIS; DRUG APPROVAL; DRUG DESIGN; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; NONHUMAN; POSTAL MAIL; REVIEW; SOCIETY; SOLDIER; UNITED STATES; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL PROTEINS; BACTERIAL TOXINS; DRUG APPROVAL; HUMANS; RECOMBINANT PROTEINS; SPORES, BACTERIAL; VACCINATION; VACCINES, DNA;

BACILLUS ANTHRACIS;

EID: 70350726218     PISSN: 00982997     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mam.2009.08.006     Document Type: Review

References (184)

1. Albrecht M.T., Li H., Williamson E.D., LeButt C.S., Flick-Smith H.C., Quinn C.P., Westra H., Galloway D., Mateczun A., Goldman S., Groen H., and Baillie L.W. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax. Infect. Immun. 75 (2007) 5425-5433
2. Aloni-Grinstein R., Gat O., Altboum Z., Velan B., Cohen S., and Shafferman A. Oral spore vaccine based on live attenuated nontoxinogenic Bacillus anthracis expressing recombinant mutant protective antigen. Infect. Immun. 73 (2005) 4043-4053
3. Ascenzi P., Visca P., Ippolito G., Spallarossa A., Bolognesi M., and Montecucco C. Anthrax toxin: a tripartite lethal combination. FEBS Lett. 531 (2002) 384-388
4. Auerbach S., and Wright G.G. Studies on immunity in anthrax. VI. Immunizing activity of protective antigen against various strains of Bacillus anthracis. J. Immunol. 75 (1955) 129-133
5. Aulinger B.A., Roehrl M.H., Mekalanos J.J., Collier R.J., and Wang J.Y. Combining anthrax vaccine and therapy: a dominant-negative inhibitor of anthrax toxin is also a potent and safe immunogen for vaccines. Infect. Immun. 73 (2005) 3408-3414
6. Baccam P., and Boechler M. Public health response to an anthrax attack: an evaluation of vaccination policy options. Biosecur. Bioterror. 5 (2007) 26-34
7. Baillie L. The development of new vaccines against Bacillus anthracis. J. Appl. Microbiol. 91 (2001) 609-613
8. Baillie L., Hebdon R., Flick-Smith H., and Williamson D. Characterisation of the immune response to the UK human anthrax vaccine. FEMS Immunol. Med. Microbiol. 36 (2003) 83-86
9. Baillie L., Townend T., Walker N., Eriksson U., and Williamson D. Characterization of the human immune response to the UK anthrax vaccine. FEMS Immunol. Med. Microbiol. 42 (2004) 267-270
10. Baillie L.W., Rodriguez A.L., Moore S., Atkins H.S., Feng C., Nataro J.P., and Pasetti M.F. Towards a human oral vaccine for anthrax: the utility of a Salmonella typhi Ty21a-based prime-boost immunization strategy. Vaccine 26 (2008) 6083-6091
11. Barnard J.P., and Friedlander A.M. Vaccination against anthrax with attenuated recombinant strains of Bacillus anthracis that produce protective antigen. Infect. Immun. 67 (1999) 562-567
12. Barnes J.M. The development of anthrax following the administration of spores by inhalation. Br. J. Exp. Pathol. 28 (1947) 385-394
13. Beedham R.J., Turnbull P.C., and Williamson E.D. Passive transfer of protection against Bacillus anthracis infection in a murine model. Vaccine 19 (2001) 4409-4416
14. Belton F.C., and Strange R.E. Studies on a protective antigen produced in vitro from Bacillus anthracis: medium and methods of production. Br. J. Exp. Pathol. 35 (1954) 144-152
15. Bielinska A.U., Janczak K.W., Landers J.J., Makidon P., Sower L.E., Peterson J.W., and Baker Jr. J.R. Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge. Infect. Immun. 75 (2007) 4020-4029
16. Brachman P.S., Gold H., Plotkin S.A., Fekety F.R., Werrin M., and Ingraham N.R. Field evaluation of a human anthrax vaccine. Am. J. Public Health Nations Health 52 (1962) 632-645
17. Brahmbhatt T.N., Darnell S.C., Carvalho H.M., Sanz P., Kang T.J., Bull R.L., Rasmussen S.B., Cross A.S., and O'Brien A.D. Recombinant exosporium protein BclA of Bacillus anthracis is effective as a booster for mice primed with suboptimal amounts of protective antigen. Infect. Immun. 75 (2007) 5240-5247
18. Brey R.N. Molecular basis for improved anthrax vaccines. Adv. Drug Deliv. Rev. 57 (2005) 1266-1292
19. Brossier F., Levy M., and Mock M. Anthrax spores make an essential contribution to vaccine efficacy. Infect. Immun. 70 (2002) 661-664
20. Brossier F., Weber-Levy M., Mock M., and Sirard J.C. Role of toxin functional domains in anthrax pathogenesis. Infect. Immun. 68 (2000) 1781-1786
21. Campbell J.D., Clement K.H., Wasserman S.S., Donegan S., Chrisley L., and Kotloff K.L. Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults. Hum. Vaccine 3 (2007) 205-211
22. Casadevall A. Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg. Infect. Dis. 8 (2002) 833-841
23. Chabot D.J., Scorpio A., Tobery S.A., Little S.F., Norris S.L., and Friedlander A.M. Anthrax capsule vaccine protects against experimental infection. Vaccine 23 (2004) 43-47
24. Coeshott C.M., Smithson S.L., Verderber E., Samaniego A., Blonder J.M., Rosenthal G.J., and Westerink M.A. Pluronic F127-based systemic vaccine delivery systems. Vaccine 22 (2004) 2396-2405
25. Cohen S., Mendelson I., Altboum Z., Kobiler D., Elhanany E., Bino T., Leitner M., Inbar I., Rosenberg H., Gozes Y., Barak R., Fisher M., Kronman C., Velan B., and Shafferman A. Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax. Infect. Immun. 68 (2000) 4549-4558
26. Cybulski Jr. R.J., Sanz P., McDaniel D., Darnell S., Bull R.L., and O'Brien A.D. Recombinant Bacillus anthracis spore proteins enhance protection of mice primed with suboptimal amounts of protective antigen. Vaccine 26 (2008) 4927-4939
27. Dong S.L. Progress in the control and research of anthrax in China. Salisb. Med. Bull. 68 (1990) 104
28. Edelman R. An overview of adjuvant use. In: O'Hagan D.T. (Ed). Vaccine Adjuvants (2000), Humana Press, Inc., Totowa, NJ 1-27
29. Ezzell J.W., and Welkos S.L. The capsule of Bacillus anthracis, a review. J. Appl. Microbiol. 87 (1999) 250
30. Fellows P.F., Linscott M.K., Ivins B.E., Pitt M.L., Rossi C.A., Gibbs P.H., and Friedlander A.M. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 19 (2001) 3241-3247
31. Flick-Smith H.C., Eyles J.E., Hebdon R., Waters E.L., Beedham R.J., Stagg T.J., Miller J., Alpar H.O., Baillie L.W., and Williamson E.D. Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice. Infect. Immun. 70 (2002) 2022-2028
32. Fowler R.A., Sanders G.D., Bravata D.M., Nouri B., Gastwirth J.M., Peterson D., Broker A.G., Garber A.M., and Owens D.K. Cost-effectiveness of defending against bioterrorism: a comparison of vaccination and antibiotic prophylaxis against anthrax. Ann. Intern. Med. 142 (2005) 601-610
33. Friedlander A.M., Pittman P.R., and Parker G.W. Anthrax vaccine: evidence for safety and efficacy against inhalational anthrax. JAMA 282 (1999) 2104-2106
34. Friedlander A.M., Welkos S.L., Pitt M.L., Ezzell J.W., Worsham P.L., Rose K.J., Ivins B.E., Lowe J.R., Howe G.B., and Mikesell P. Postexposure prophylaxis against experimental inhalation anthrax. J. Infect. Dis. 167 (1993) 1239-1243
35. Galen J.E., Zhao L., Chinchilla M., Wang J.Y., Pasetti M.F., Green J., and Levine M.M. Adaptation of the endogenous Salmonella enterica serovar Typhi clyA-encoded hemolysin for antigen export enhances the immunogenicity of anthrax protective antigen domain 4 expressed by the attenuated live-vector vaccine strain CVD 908-htrA. Infect. Immun. 72 (2004) 7096-7106
36. Galloway D., Liner A., Legutki J., Mateczun A., Barnewall R., and Estep J. Genetic immunization against anthrax. Vaccine 22 (2004) 1604-1608
37. Garmory H.S., Titball R.W., Griffin K.F., Hahn U., Bohm R., and Beyer W. Salmonella enterica serovar typhimurium expressing a chromosomally integrated copy of the Bacillus anthracis protective antigen gene protects mice against an anthrax spore challenge. Infect. Immun. 71 (2003) 3831-3836
38. Gaur R., Gupta P.K., Banerjea A.C., and Singh Y. Effect of nasal immunization with protective antigen of Bacillus anthracis on protective immune response against anthrax toxin. Vaccine 20 (2002) 2836-2839
39. Gauthier Y.P., Tournier J.N., Paucod J.C., Corre J.P., Mock M., Goossens P.L., and Vidal D.R. Efficacy of a vaccine based on protective antigen and killed spores against experimental inhalational anthrax. Infect. Immun. 77 (2009) 1197-1207
40. Geier D.A., and Geier M.R. Anthrax vaccination and joint related adverse reactions in light of biological warfare scenarios. Clin. Exp. Rheumatol. 20 (2002) 217-220
41. Geier M.R., and Geier D.A. Gastrointestinal adverse reactions following anthrax vaccination: an analysis of the vaccine adverse events reporting system (VAERS) database. Hepatogastroenterology 51 (2004) 762-767
42. Glomski I.J., Fritz J.H., Keppler S.J., Balloy V., Chignard M., Mock M., and Goossens P.L. Murine splenocytes produce inflammatory cytokines in a MyD88-dependent response to Bacillus anthracis spores. Cell Microbiol. 9 (2007) 502-513
43. Goodman J.W., and Nitecki D.E. Immunochemical studies on the poly-g-d-glutamyl capsule of Bacillus anthracis. I. Characterization of the polypeptide and of the specificity of its reaction with rabbit antisera. Biochemistry 5 (1966) 657-665
44. Gorse G.J., Keitel W., Keyserling H., Taylor D.N., Lock M., Alves K., Kenner J., Deans L., and Gurwith M. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial. Vaccine 24 (2006) 5950-5959
45. Grabenstein J.D. Vaccines: countering anthrax: vaccines and immunoglobulins. Clin. Infect. Dis. 46 (2008) 129-136
46. Grabenstein J.D., Pittman P.R., Greenwood J.T., and Engler R.J. Immunization to protect the US Armed Forces: heritage, current practice, and prospects. Epidemiol. Rev. 28 (2006) 3-26
47. Greidanus T.G., and Honl B.A. Delayed-type hypersensitivity reaction to anthrax vaccine. Mil. Med. 167 (2002) 74-75
48. Gu M.L., Leppla S.H., and Klinman D.M. Protection against anthrax toxin by vaccination with a DNA plasmid encoding anthrax protective antigen. Vaccine 17 (1999) 340-344
49. Hachisuka Y., Kojima K., and Sato T. Fine filaments on the outside of the exosporium of Bacillus anthracis spores. J. Bacteriol. 91 (1966) 2382-2384
50. Hahn U.K., Boehm R., and Beyer W. DNA vaccination against anthrax in mice-combination of anti-spore and anti-toxin components. Vaccine 24 (2006) 4569-4571
51. Hahn U.K., Aichler M., Boehm R., and Beyer W. Comparison of the immunological memory after DNA vaccination and protein vaccination against anthrax in sheep. Vaccine 24 (2006) 4595-4597
52. Hambleton P., Carman J.A., and Melling J. Anthrax: the disease in relation to vaccines. Vaccine 2 (1984) 125-132
53. Harrison L.H., Ezzell J.W., Abshire T.G., Kidd S., and Kaufmann A.F. Evaluation of serologic tests for diagnosis of anthrax after an outbreak of cutaneous anthrax in Paraguay. J. Infect. Dis. 160 (1989) 706-710
54. Hashimoto M., Boyer J.L., Hackett N.R., Wilson J.M., and Crystal R.G. Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity. Infect. Immun. 73 (2005) 6885-6891
55. Henderson D.W., Peacock S., and Belton F.C. Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J. Hyg. 54 (1956) 28-36
56. Hepler R.W., Kelly R., McNeely T.B., Fan H., Losada M.C., George H.A., Woods A., Cope L.D., Bansal A., Cook J.C., Zang G., Cohen S.L., Wei X., Keller P.M., Leffel E., Joyce J.G., Pitt L., Schultz L.D., Jansen K.U., and Kurtz M. A recombinant 63-kDa form of Bacillus anthracis protective antigen produced in the yeast Saccharomyces cerevisiae provides protection in rabbit and primate inhalational challenge models of anthrax infection. Vaccine 24 (2006) 1501-1514
57. Hermanson G., Whitlow V., Parker S., Tonsky K., Rusalov D., Ferrari M., Lalor P., Komai M., Mere R., Bell M., Brenneman K., Mateczun A., Evans T., Kaslow D., Galloway D., and Hobart P. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Proc. Natl. Acad. Sci. USA 101 (2004) 13601-13606
58. Hewetson J.F., Little S.F., Ivins B.E., Johnson W.M., Pittman P.R., Brown J.E., Norris S.L., and Nielsen C.J. An in vivo passive protection assay for the evaluation of immunity in AVA-vaccinated individuals. Vaccine 26 (2008) 4262-4266
59. Hoffman K., Costello C., Menich M., Grabenstein J.D., and Engler R.J. Using a structured medical note for determining the safety profile of anthrax vaccine for US soldiers in Korea. Vaccine 21 (2003) 4399-4409
60. Huang J., Mikszta J.A., Ferriter M.S., Jiang G., Harvey N.G., Dyas B., Roy C.J., Ulrich R.G., and Sullivan V.J. Intranasal administration of dry powder anthrax vaccine provides protection against lethal aerosol spore challenge. Hum. Vaccine 3 (2007) 90-93
61. Hunter D., Zoutman D., Whitehead J., Hutchings J., and MacDonald K. Health effects of anthrax vaccination in the Canadian forces. Mil. Med. 169 (2004) 833-838
62. Ivins B., Fellows P., Pitt L., Estep J., Farchaus J., Friedlander A., and Gibbs P. Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs. Vaccine 13 (1995) 1779-1784
63. Ivins B.E., Ezzell Jr. J.W., Jemski J., Hedlund K.W., Ristroph J.D., and Leppla S.H. Immunization studies with attenuated strains of Bacillus anthracis. Infect. Immun. 52 (1986) 454-458
64. Ivins B.E., Pitt M.L., Fellows P.F., Farchaus J.W., Benner G.E., Waag D.M., Little S.F., Anderson Jr. G.W., Gibbs P.H., and Friedlander A.M. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 16 (1998) 1141-1148
65. Ivins B.E., Welkos S.L., Knudson G.B., and Little S.F. Immunization against anthrax with aromatic compound-dependent (Aro-) mutants of Bacillus anthracis and with recombinant strains of Bacillus subtilis that produce anthrax protective antigen. Infect. Immun. 58 (1990) 303-308
66. Ivins B.E., Welkos S.L., Little S.F., Crumrine M.H., and Nelson G.O. Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants. Infect. Immun. 60 (1992) 662-668
67. Jernigan D.B., Raghunathan P.L., Bell B.P., Brechner R., Bresnitz E.A., Butler J.C., Cetron M., Cohen M., Doyle T., Fischer M., Greene C., Griffith K.S., Guarner J., Hadler J.L., Hayslett J.A., Meyer R., Petersen L.R., Phillips M., Pinner R., Popovic T., Quinn C.P., Reefhuis J., Reissman D., Rosenstein N., Schuchat A., Shieh W.J., Siegal L., Swerdlow D.L., Tenover F.C., Traeger M., Ward J.W., Weisfuse I., Wiersma S., Yeskey K., Zaki S., Ashford D.A., Perkins B.A., Ostroff S., Hughes J., Fleming D., Koplan J.P., and Gerberding J.L. Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg. Infect. Dis 8 (2002) 1019-1028
68. Jernigan J.A., Stephens D.S., Ashford D.A., Omenaca C., Topiel M.S., Galbraith M., Tapper M., Fisk T.L., Zaki S., Popovic T., Meyer R.F., Quinn C.P., Harper S.A., Fridkin S.K., Sejvar J.J., Shepard C.W., McConnell M., Guarner J., Shieh W.J., Malecki J.M., Gerberding J.L., Hughes J.M., and Perkins B.A. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg. Infect. Dis. 7 (2001) 933-944
69. Joellenbeck L.M., Zwanziger L.L., Durch J.S., and Strom B.L. The Anthrax Vaccine: Is It Safe? Does It Work? (2002), National Academy Press, Washington, DC
70. Joyce J., Cook J., Chabot D., Hepler R., Shoop W., Xu Q., Stambaugh T., ste-Amezaga M., Wang S., Indrawati L., Bruner M., Friedlander A., Keller P., and Caulfield M. Immunogenicity and protective efficacy of Bacillus anthracis poly-g-D-glutamic acid capsule covalently coupled to a protein carrier using a novel triazine-based conjugation strategy. J. Biol. Chem. 281 (2006) 4831-4843
71. Keitel W.A. Recombinant protective antigen 102 (rPA102): profile of a second-generation anthrax vaccine. Expert Rev. Vaccines. 5 (2006) 417-430
72. Kenney R.T., Yu J., Guebre-Xabier M., Frech S.A., Lambert A., Heller B.A., Ellingsworth L.R., Eyles J.E., Williamson E.D., and Glenn G.M. Induction of protective immunity against lethal anthrax challenge with a patch. J. Infect. Dis. 190 (2004) 774-782
73. Keppie J., Smith H., and Harris-Smith P.W. The chemical basis of the virulence of Bacillus anthracis. III. The role of the terminal bacteraemia in death of guinea-pigs from anthrax. Br. J. Exp. Pathol. 36 (1955) 315-322
74. Klas S.D., Petrie C.R., Warwood S.J., Williams M.S., Olds C.L., Stenz J.P., Cheff A.M., Hinchcliffe M., Richardson C., and Wimer S. A single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challenge. Vaccine 26 (2008) 5494-5502
75. Klein F., Dearmon Jr. I.A., Lincoln R.E., Mahlandt B.G., and FerneliusA L. Immunological studies of anthrox. II. Levels of immunity against Bacillus anthracis obtained with protective antigen and live vaccine. J. Immunol. 88 (1962) 15-19
76. Klinman D.M., Xie H., Little S.F., Currie D., and Ivins B.E. CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques. Vaccine 22 (2004) 2881-2886
77. Knockenhauer K.E., Sawicka K.M., Roemer E.J., and Simon S.R. Protective antigen composite nanofibers as a transdermal anthrax vaccine. Conf. Proc. IEEE Eng. Med. Biol. Soc. 1 (2008) 1040-1043
78. Kobiler D., Gozes Y., Rosenberg H., Marcus D., Reuveny S., and Altboum Z. Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization. Infect. Immun. 70 (2002) 544-560
79. Kozel T.R., Murphy W.J., Brandt S., Blazar B.R., Lovchik J.A., Thorkildson P., Percival A., and Lyons C.R. MAbs to Bacillus anthracis capsular antigen for immunoprotection in anthrax and detection of antigenemia. Proc. Natl. Acad. Sci. USA 101 (2004) 5042-5047
80. Kozel T.R., Thorkildson P., Brandt S., Welch W.H., Lovchik J.A., AuCoin D.P., Vilai J., and Lyons C.R. Protective and immunochemical activities of monoclonal antibodies reactive with the Bacillus anthracis polypeptide capsule. Infect. Immun. 75 (2007) 152-163
81. Lange J.L., Lesikar S.E., Rubertone M.V., and Brundage J.F. Comprehensive systematic surveillance for adverse effects of anthrax vaccine adsorbed, US Armed Forces, 1998-2000. Vaccine 21 (2003) 1620-1628
82. Lee J.S., Hadjipanayis A.G., and Welkos S.L. Venezuelan equine encephalitis virus-vectored vaccines protect mice against anthrax spore challenge. Infect. Immun. 71 (2003) 1491-1496
83. Little S.F. Anthrax vaccines: a development update. BioDrugs 19 (2005) 233-245
84. Little S.F., Ivins B.E., Fellows P.F., and Friedlander A.M. Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect. Immun. 65 (1997) 5171-5175
85. Little S.F., Ivins B.E., Fellows P.F., Pitt M.L., Norris S.L., and Andrews G.P. Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine 22 (2004) 422-430
86. Little S.F., Ivins B.E., Webster W.M., Fellows P.F., Pitt M.L., Norris S.L., and Andrews G.P. Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine. Vaccine 24 (2006) 2530-2536
87. Little S.F., and Knudson G.B. Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig. Infect. Immun. 52 (1986) 509-512
88. Liu T.H., Oscherwitz J., Schnepp B., Jacobs J., Yu F., Cease K.B., and Johnson P.R. Genetic vaccines for anthrax based on recombinant adeno-associated virus vectors. Mol. Ther. 17 (2009) 373-379
89. Luxembourg A., Hannaman D., Nolan E., Ellefsen B., Nakamura G., Chau L., Tellez O., Little S., and Bernard R. Potentiation of an anthrax DNA vaccine with electroporation. Vaccine 26 (2008) 5216-5222
90. Mabry R., Rani M., Geiger R., Hubbard G.B., Carrion Jr. R., Brasky K., Patterson J.L., Georgiou G., and Iverson B.L. Passive protection against anthrax by using a high-affinity antitoxin antibody fragment lacking an Fc region. Infect. Immun. 73 (2005) 8362-8368
91. Marano N., Plikaytis B.D., Martin S.W., Rose C., Semenova V.A., Martin S.K., Freeman A.E., Li H., Mulligan M.J., Parker S.D., Babcock J., Keitel W., El S.H., Poland G.A., Jacobson R.M., Keyserling H.L., Soroka S.D., Fox S.P., Stamper J.L., McNeil M.M., Perkins B.A., Messonnier N., and Quinn C.P. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. JAMA 300 (2008) 1532-1543
92. Marcus H., Danieli R., Epstein E., Velan B., Shafferman A., and Reuveny S. Contribution of immunological memory to protective immunity conferred by a Bacillus anthracis protective antigen-based vaccine. Infect. Immun. 72 (2004) 3471-3477
93. Matyas G.R., Friedlander A.M., Glenn G.M., Little S., Yu J., and Alving C.R. Needle-free skin patch vaccination method for anthrax. Infect. Immun. 72 (2004) 1181-1183
94. McBride B.W., Mogg A., Telfer J.L., Lever M.S., Miller J., Turnbull P.C., and Baillie L. Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers. Vaccine 16 (1998) 810-817
95. McNeil M.M., Chiang I.S., Wheeling J.T., and Zhang Y. Short-term reactogenicity and gender effect of anthrax vaccine: analysis of a 1967-1972 study and review of the 1955-2005 medical literature. Pharmacoepidemiol. Drug Safety 16 (2007) 259-274
96. Mendelson I., Gat O., oni-Grinstein R., Altboum Z., Inbar I., Kronman C., Bar-Haim E., Cohen S., Velan B., and Shafferman A. Efficacious, nontoxigenic Bacillus anthracis spore vaccines based on strains expressing mutant variants of lethal toxin components. Vaccine 23 (2005) 5688-5697
97. Midha S., and Bhatnagar R. Anthrax protective antigen administered by DNA vaccination to distinct subcellular locations potentiates humoral and cellular immune responses. Eur. J. Immunol. 39 (2009) 159-177
98. Mikszta J.A., Dekker III J.P., Harvey N.G., Dean C.H., Brittingham J.M., Huang J., Sullivan V.J., Dyas B., Roy C.J., and Ulrich R.G. Microneedle-based intradermal delivery of the anthrax recombinant protective antigen vaccine. Infect. Immun. 74 (2006) 6806-6810
99. Mikszta J.A., Sullivan V.J., Dean C., Waterston A.M., Alarcon J.B., Dekker III J.P., Brittingham J.M., Huang J., Hwang C.R., Ferriter M., Jiang G., Mar K., Saikh K.U., Stiles B.G., Roy C.J., Ulrich R.G., and Harvey N.G. Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms. J. Infect. Dis. 191 (2005) 278-288
100. Mock M., and Fouet A. Anthrax. Annu. Rev. Microbiol. 55 (2001) 647-671
101. Mohamadzadeh M., Duong T., Hoover T., and Klaenhammer T.R. Targeting mucosal dendritic cells with microbial antigens from probiotic lactic acid bacteria. Expert Rev. Vaccines 7 (2008) 163-174
102. Mohamadzadeh, M., Duong, T., Sandwick, S.J., Hoover, T., Klaenhammer, T.R., 2009. Dendritic cell targeting of Bacillus anthracis protective antigen expressed by Lactobacillus acidophilus protects mice from lethal challenge. Proc. Natl. Acad. Sci. USA
103. Mohamed N., Clagett M., Li J., Jones S., Pincus S., D'Alia G., Nardone L., Babin M., Spitalny G., and Casey L. A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect. Immun. 73 (2005) 795-802
104. Mohamed N., Li J., Ferreira C.S., Little S.F., Friedlander A.M., Spitalny G.L., and Casey L.S. Enhancement of anthrax lethal toxin cytotoxicity: a subset of monoclonal antibodies against protective antigen increases lethal toxin-mediated killing of murine macrophages. Infect. Immun. 72 (2004) 3276-3283
105. Molnar D.M., and Altenburn R.A. Alterations in the biological activity of protective antigen of Bacillus anthracis toxin. Proc. Soc. Exp. Biol. Med. 114 (1963) 294-297
106. Nakouzi A., Rivera J., Rest R.F., and Casadevall A. Passive administration of monoclonal antibodies to anthrolysin O prolong survival in mice lethally infected with Bacillus anthracis. BMC Microbiol. 8 (2008) 159
107. Nass M. Anthrax vaccine. Model of a response to the biologic warfare threat. Infect. Dis. Clin. North Am. 13 (1999) 187-208 viii
108. Niu M.T., Ball R., Woo E.J., Burwen D.R., Knippen M., and Braun M.M. Adverse events after anthrax vaccination reported to the vaccine adverse event reporting system (VAERS), 1990-2007. Vaccine 27 (2009) 290-297
109. Osorio M., Wu Y., Singh S., Merkel T.J., Bhattacharyya S., Blake M.S., and Kopecko D.J. Anthrax protective antigen delivered by Salmonella enterica serovar Typhi Ty21a protects mice from a lethal anthrax spore challenge. Infect. Immun. 77 (2009) 1475-1482
110. Payne D.C., Franzke L.H., Stehr-Green P.A., Schwartz B., and McNeil M.M. Development of the Vaccine Analytic Unit's research agenda for investigating potential adverse events associated with anthrax vaccine adsorbed. Pharmacoepidemiol. Drug Safety 16 (2007) 46-54
111. Peachman K.K., Rao M., Alving C.R., Burge R., Leppla S.H., Rao V.B., and Matyas G.R. Correlation between lethal toxin-neutralizing antibody titers and protection from intranasal challenge with Bacillus anthracis Ames strain spores in mice after transcutaneous immunization with recombinant anthrax protective antigen. Infect. Immun. 74 (2006) 794-797
112. Pelat T., Hust M., Laffly E., Condemine F., Bottex C., Vidal D., Lefranc M.P., Dübel S., and Thullier P. High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation. Antimicrob. Agents Chemother. 51 (2007) 2758-2764
113. Peterson J.W., Comer J.E., Baze W.B., Noffsinger D.M., Wenglikowski A., Walberg K.G., Hardcastle J., Pawlik J., Bush K., Taormina J., Moen S., Thomas J., Chatuev B.M., Sower L., Chopra A.K., Stanberry L.R., Sawada R., Scholz W.W., and Sircar J. Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of the Bacillus anthracis Ames strain from the lungs in a rabbit model. Infect. Immun. 75 (2007) 3414-3424
114. Peterson J.W., Comer J.E., Noffsinger D.M., Wenglikowski A., Walberg K.G., Chatuev B.M., Chopra A.K., Stanberry L.R., Kang A.S., Scholz W.W., and Sircar J. Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax. Infect. Immun. 74 (2006) 1016-1024
115. Pezard C., Berche P., and Mock M. Contribution of individual toxin components to virulence of Bacillus anthracis. Infect. Immun. 59 (1991) 3472-3477
116. Pezard C., Weber M., Sirard J.C., Berche P., and Mock M. Protective immunity induced by Bacillus anthracis toxin-deficient strains. Infect. Immun. 63 (1995) 1369-1372
117. Pitt M.L., Little S., Ivins B.E., Fellows P., Boles J., Barth J., Hewetson J., and Friedlander A.M. In vitro correlate of immunity in an animal model of inhalational anthrax. J. Appl. Microbiol. 87 (1999) 304
118. Pitt M.L., Little S.F., Ivins B.E., Fellows P., Barth J., Hewetson J., Gibbs P., Dertzbaugh M., and Friedlander A.M. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 19 (2001) 4768-4773
119. Pittman P.R., Coonan K.M., Gibbs P.H., Scott H.M., Cannon T.L., and McKee Jr. K.T. Long-term health effects of repeated exposure to multiple vaccines. Vaccine 23 (2004) 525-536
120. Pittman P.R., Gibbs P.H., Cannon T.L., and Friedlander A.M. Anthrax vaccine: short-term safety experience in humans. Vaccine 20 (2001) 972-978
121. Pittman P.R., Kim-Ahn G., Pifat D.Y., Coonan K., Gibbs P., Little S., Pace-Templeton J.G., Myers R., Parker G.W., and Friedlander A.M. Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine 20 (2002) 1412-1420
122. Pittman P.R., Leitman S.F., Oro J.G., Norris S.L., Marano N.M., Ranadive M.V., Sink B.S., and McKee Jr. K.T. Protective antigen and toxin neutralization antibody patterns in anthrax vaccinees undergoing serial plasmapheresis. Clin. Diagn. Lab Immunol. 12 (2005) 713-721
123. Pittman P.R., Mangiafico J.A., Rossi C.A., Cannon T.L., Gibbs P.H., Parker G.W., and Friedlander A.M. Anthrax vaccine: increasing intervals between the first two doses enhances antibody response in humans. Vaccine 19 (2000) 213-216
124. Pittman P.R., Norris S.L., Barrera Oro J.G., Bedwell D., Cannon T.L., and McKee Jr. K.T. Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series. Vaccine 24 (2006) 3654-3660
125. Price B.M., Liner A.L., Park S., Leppla S.H., Mateczun A., and Galloway D.R. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect. Immun. 69 (2001) 4509-4515
126. Puziss M., and Wright G.G. Studies on immunity in anthrax. IV. Factors influencing elaboration of the protective antigen of Bacillus anthracis in chemically defined media. J. Bacteriol. (1954) 474-482
127. Ramirez D.M., Leppla S.H., Schneerson R., and Shiloach J. Production, recovery and immunogenicity of the protective antigen from a recombinant strain of Bacillus anthracis. J. Ind. Microbiol. Biotechnol. 28 (2002) 232-238
128. Reuveny S., White M.D., Adar Y.Y., Kafri Y., Altboum Z., Gozes Y., Kobiler D., Shafferman A., and Velan B. Search for correlates of protective immunity conferred by anthrax vaccine. Infect. Immun. 69 (2001) 2888-2893
129. Rhie G.E., Park Y.M., Han J.S., Yu J.Y., Seong W.K., and Oh H.B. Efficacy of non-toxic deletion mutants of protective antigen from Bacillus anthracis. FEMS Immunol. Med. Microbiol. 45 (2005) 341-347
130. Rhie G.E., Roehrl M.H., Mourez M., Collier R.J., Mekalanos J.J., and Wang J.Y. A dually active anthrax vaccine that confers protection against both bacilli and toxins. Proc. Natl. Acad. Sci. USA 100 (2003) 10925-10930
131. Ribot W.J., Panchal R.G., Brittingham K.C., Ruthel G., Kenny T.A., Lane D., Curry B., Hoover T.A., Friedlander A.M., and Bavari S. Anthrax lethal toxin impairs innate immune functions of alveolar macrophages and facilitates Bacillus anthracis survival. Infect. Immun. 74 (2006) 5029-5034
132. Riemenschneider J., Garrison A., Geisbert J., Jahrling P., Hevey M., Negley D., Schmaljohn A., Lee J., Hart M.K., Vanderzanden L., Custer D., Bray M., Ruff A., Ivins B., Bassett A., Rossi C., and Schmaljohn C. Comparison of individual and combination DNA vaccines for B. Anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine 21 (2003) 4071-4080
133. Sawada-Hirai R., Jiang I., Wang F., Sun S.M., Nedellec R., Ruther P., Alvarez A., Millis D., Morrow P.R., and Kang A.S. Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed. J. Immune Based Ther. Vaccines 2 (2004) 5
134. Schneerson R., Kubler-Kielb J., Liu T.Y., Dai Z.D., Leppla S.H., Yergey A., Backlund P., Shiloach J., Majadly F., and Robbins J.B. Poly(gamma-d-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: a potential addition to the anthrax vaccine. Proc. Natl. Acad. Sci. USA 100 (2003) 8945-8950
135. Sellman B.R., Mourez M., and Collier R.J. Dominant-negative mutants of a toxin subunit: an approach to therapy of anthrax. Science 292 (2001) 695-697
136. Sellman B.R., Nassi S., and Collier R.J. Point mutations in anthrax protective antigen that block translocation. J. Biol. Chem. 276 (2001) 8371-8376
137. Sever J.L., Brenner A.I., Gale A.D., Lyle J.M., Moulton L.H., Ward B.J., and West D.J. Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the vaccine adverse event reporting system (VAERS). Pharmacoepidemiol. Drug Safety 13 (2004) 825-840
138. Shivachandra S.B., Li Q., Peachman K.K., Matyas G.R., Leppla S.H., Alving C.R., Rao M., and Rao V.B. Multicomponent anthrax toxin display and delivery using bacteriophage T4. Vaccine 25 (2007) 1225-1235
139. Shlyakhov E.N., and Rubinstein E. Human live anthrax vaccine in the former USSR. Vaccine 12 (1994) 727-730
140. Singer D.E., Schneerson R., Bautista C.T., Rubertone M.V., Robbins J.B., and Taylor D.N. Serum IgG antibody response to the protective antigen (PA) of Bacillus anthracis induced by anthrax vaccine adsorbed (AVA) among US. Mil. Personnel. Vaccine 26 (2008) 869-873
141. Singh Y., Khanna H., Chopra A.P., and Mehra V. A dominant negative mutant of Bacillus anthracis protective antigen inhibits anthrax toxin action in vivo. J Biol. Chem. 276 (2001) 22090-22094
142. Sirisanthana T., Nelson K.E., Ezzell J.W., and Abshire T.G. Serological studies of patients with cutaneous and oral-oropharyngeal anthrax from northern Thailand. Am. J Trop. Med. Hyg. 39 (1988) 575-581
143. Skoble J., Beaber J.W., Gao Y., Lovchik J.A., Sower L.E., Liu W., Luckett W., Peterson J.W., Calendar R., Portnoy D.A., Lyons C.R., and Dubensky Jr. T.W. Killed but metabolically active bacillus anthracis vaccines induce broad and protective immunity against anthrax. Infect. Immun. 77 (2009) 1649-1663
144. Sloat B.R., and Cui Z. Nasal immunization with a dual antigen anthrax vaccine induced strong mucosal and systemic immune responses against toxins and bacilli. Vaccine 24 (2006) 6405-6413
145. Sloat B.R., and Cui Z. Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities. Pharm. Res. 23 (2006) 1217-1226
146. Smith B., Leard C.A., Smith T.C., Reed R.J., and Ryan M.A. Anthrax vaccination in the Millennium Cohort: validation and measures of health. Am. J. Prev. Med. 32 (2007) 347-353
147. Smith H., Keppie J., and Stanley J.L. The chemical basis of the virulence of Bacillus anthracis. V. The specific toxin produced by B. Anthracis in vivo. Br. J. Exp. Pathol. 36 (1955) 460-472
148. Smith H., Keppie J., Stanley J.L., and Harris-Smith P.W. The chemical basis of the virulence of Bacillus anthracis. IV. Secondary shock as the major factor in death of guinea-pigs from anthrax. Br. J. Exp. Pathol. 36 (1955) 323-335
149. Staats H.F., Alam S.M., Scearce R.M., Kirwan S.M., Zhang J.X., Gwinn W.M., and Haynes B.F. In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity. Infect. Immun. 75 (2007) 5443-5452
150. Steichen C.T., Kearney J.F., and Turnbough Jr. C.L. Characterization of the exosporium basal layer protein BxpB of Bacillus anthracis. J. Bacteriol. 187 (2005) 5868-5876
151. Sternbach G. The history of anthrax. J. Emerg. Med. 24 (2003) 463-467
152. Sterne M. The use of anthrax vaccines prepared from avirulent (uncapsulated) variants of Bacillus anthracis. Onderstepoort J. Vet. Sci. Anim. Ind. 13 (1939) 307-312
153. Stokes M.G., Titball R.W., Neeson B.N., Galen J.E., Walker N.J., Stagg A.J., Jenner D.C., Thwaite J.E., Nataro J.P., Baillie L.W., and Atkins H.S. Oral administration of a Salmonella enterica-based vaccine expressing Bacillus anthracis protective antigen confers protection against aerosolized B. anthracis. Infect. Immun. 75 (2007) 1827-1834
154. Swanson-Biearman B., and Krenzelok E.P. Delayed life-threatening reaction to anthrax vaccine. J. Toxicol. Clin. Toxicol. 39 (2001) 81-84
155. Sylvestre P., Couture-Tosi E., and Mock M. A collagen-like surface glycoprotein is a structural component of the Bacillus anthracis exosporium. Mol. Microbiol. 45 (2002) 169-178
156. Takeshita F., Gursel I., Ishii K.J., Suzuki K., Gursel M., and Klinman D.M. Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9. Semin. Immunol 16 (2004) 17-22
157. The Jackson Laboratory, 2008. A/J Strain Information Page. .
158. Tigertt W.D. Anthrax. William Smith Greenfield, M.D., F.R.C.P., professor superintendent, the Brown Animal Sanatory Institution (1878-81) concerning the priority due to him for the production of the first vaccine against anthrax. J. Hyg. (Lond.) 85 (1980) 415-420
159. Tournier J.N., Ulrich R.G., Quesnel-Hellmann A., Mohamadzadeh M., and Stiles B.G. Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis. Expert Rev. Anti. Infect. Ther. 7 (2009) 219-236
160. Turnbull P.C. Anthrax vaccines: past, present and future. Vaccine 9 (1991) 533-539
161. Turnbull P.C. Current status of immunization against anthrax: old vaccines may be here to stay for a while. Curr. Opin. Infect. Dis. 13 (2000) 113-120
162. Turnbull P.C., Leppla S.H., Broster M.G., Quinn C.P., and Melling J. Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Med. Microbiol. Immunol. 177 (1988) 293-303
163. Vasudev M., and Zacharisen M.C. New-onset rheumatoid arthritis after anthrax vaccination. Ann. Allergy Asthma Immunol. 97 (2006) 110-112
164. Wang J.Y., and Roehrl M.H. Anthrax vaccine design: strategies to achieve comprehensive protection against spore, bacillus, and toxin. Med. Immunol. 4 (2005) 4
165. Wang T.T., Fellows P.F., Leighton T.J., and Lucas A.H. Induction of opsonic antibodies to the g-D-glutamic acid capsule of Bacillus anthracis by immunization with a synthetic peptide-carrier protein conjugate. FEMS Immunol. Med. Microbiol. 40 (2004) 231-237
166. Wasserman G.M., Grabenstein J.D., Pittman P.R., Rubertone M.V., Gibbs P.P., Wang L.Z., and Golder L.G. Analysis of adverse events after anthrax immunization in US Army medical personnel. J. Occup. Environ. Med. 45 (2003) 222-233
167. Weiss S., Kobiler D., Levy H., Marcus H., Pass A., Rothschild N., and Altboum Z. Immunological correlates for protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits. Infect. Immun. 74 (2006) 394-398
168. Welkos S., Friedlander A., Weeks S., Little S., and Mendelson I. In-vitro characterisation of the phagocytosis and fate of anthrax spores in macrophages and the effects of anti-PA antibody. J. Med. Microbiol. 51 (2002) 821-831
169. Welkos S., Little S., Friedlander A., Fritz D., and Fellows P. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology 147 (2001) 1677-1685
170. Welkos S.L., and Friedlander A.M. Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice. Microb. Pathog. 5 (1988) 127-139
171. Welkos S.L., and Friedlander A.M. Pathogenesis and genetic control of resistance to the Sterne strain of Bacillus anthracis. Microb. Pathog. 4 (1988) 53-69
172. Whiting G.C., Rijpkema S., Adams T., and Corbel M.J. Characterisation of adsorbed anthrax vaccine by two-dimensional gel electrophoresis. Vaccine 22 (2004) 4245-4251
173. Wild M.A., Kumor K., Nolan M.J., Lockman H., and Bowdish K.S. A human antibody against anthrax protective antigen protects rabbits from lethal infection with aerosolized spores. Hum. Antibodies 16 (2007) 99-105
174. Wild M.A., Xin H., Maruyama T., Nolan M.J., Calveley P.M., Malone J.D., Wallace M.R., and Bowdish K.S. Human antibodies from immunized donors are protective against anthrax toxin in vivo. Nat. Biotechnol. 21 (2003) 1305-1306
175. Williamson E.D., Beedham R.J., Bennett A.M., Perkins S.D., Miller J., and Baillie L.W. Presentation of protective antigen to the mouse immune system: immune sequelae. J. Appl. Microbiol. 87 (1999) 315-317
176. Williamson E.D., Hodgson I., Walker N.J., Topping A.W., Duchars M.G., Mott J.M., Estep J., Lebutt C., Flick-Smith H.C., Jones H.E., Li H., and Quinn C.P. Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax. Infect. Immun. 73 (2005) 5978-5987
177. Wimer-Mackin S., Hinchcliffe M., Petrie C.R., Warwood S.J., Tino W.T., Williams M.S., Stenz J.P., Cheff A., and Richardson C. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits. Vaccine 24 (2006) 3953-3963
178. Wright G.G., Hedberg M.A., and Slein J.B. Studies on immunity in anthrax. III. Elaboration of protective antigen in a chemically defined, non-protein medium. J. Immunol. 72 (1954) 263-269
179. Wright G.G., Hedberg M.A., and Feinberg R.J. Studies on immunity in anthrax. II. In vitro elaboration of protective antigen by non-proteolytic mutants of Bacillus anthracis. J. Exp. Med. 93 (1951) 523-527
180. Wright G.G., and Slein J.B. Studies on immunity in anthrax. I. Variation in the serum T-agglutinin during anthrax infection in the rabbit. J. Exp. Med. 93 (1951) 99-106
181. Yan M., Roehrl M.H., Basar E., and Wang J.Y. Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates. Vaccine 26 (2008) 947-955
182. Zeng M., Xu Q., and Pichichero M.E. Protection against anthrax by needle-free mucosal immunization with human anthrax vaccine. Vaccine 25 (2007) 3588-3594
183. Zhang Y., Qiu J., Zhou Y., Farhangfar F., Hester J., Lin A.Y., and Decker W.K. Plasmid-based vaccination with candidate anthrax vaccine antigens induces durable type 1 and type 2 T-helper immune responses. Vaccine 26 (2008) 614-622
184. Zhou B., Carney C., and Janda K.D. Selection and characterization of human antibodies neutralizing Bacillus anthracis toxin. Bioorg. Med. Chem. 16 (2008) 1903-1913